Carolien Bonroy

List of Publications by Year
in descending order

29	448	840119 11	752256 20
papers	citations	h-index	g-index

30	30	30	742
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays. Autoimmunity Reviews, 2019, 18, 293-305.	2.5	100
2	Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort. European Respiratory Journal, 2017, 49, 1602275.	3.1	50
3	Automated indirect immunofluorescence antinuclear antibody analysis is a standardized alternative for visual microscope interpretation. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1771-9.	1.4	43
4	A novel IKAROS haploinsufficiency kindred with unexpectedly late and variable B-cell maturation defects. Journal of Allergy and Clinical Immunology, 2018, 141, 432-435.e7.	1.5	41
5	The importance of detecting anti-DFS70 in routine clinical practice: comparison of different care settings. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1090-1099.	1.4	21
6	Persistentrotavirusdiarrhea post-transplant in a novelJAK3-SCID patient after vaccination. Pediatric Allergy and Immunology, 2016, 27, 93-96.	1.1	17
7	The immunophenotypic fingerprint of patients with primary antibody deficiencies is partially present in their asymptomatic first-degree relatives. Haematologica, 2017, 102, 192-202.	1.7	15
8	Specific anti-nuclear antibodies in systemic sclerosis patients with and without skin involvement: an extended methodological approach. Rheumatology, 2011, 50, 1302-1309.	0.9	14
9	Automated indirect immunofluorescence microscopy enables the implementation of a quantitative internal quality control system for anti-nuclear antibody (ANA) analysis. Clinical Chemistry and Laboratory Medicine, 2014, 52, 989-98.	1.4	14
10	Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey. Autoimmunity Highlights, 2020, 11, 17.	3.9	14
11	A novel LPS-responsive beige-like anchor protein (LRBA) mutation presents with normal cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and overactive TH17 immunity. Journal of Allergy and Clinical Immunology, 2018, 142, 1968-1971.	1.5	13
12	Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results. RMD Open, 2022, 8, e002099.	1.8	12
13	Improved Standardization of Flow Cytometry Diagnostic Screening of Primary Immunodeficiency by Software-Based Automated Gating. Frontiers in Immunology, 2020, 11, 584646.	2.2	11
14	The integration of the detection of systemic sclerosis-associated antibodies in a routine laboratory setting: comparison of different strategies. Clinical Chemistry and Laboratory Medicine, 2013, 51, 2151-2160.	1.4	9
15	Standardised interpretation of capillaroscopy in autoimmune idiopathic inflammatory myopathies: A structured review on behalf of the EULAR study group on microcirculation in Rheumatic Diseases. Autoimmunity Reviews, 2022, 21, 103087.	2.5	9
16	Evaluation of the primary biliary cholangitis-related serologic profile in a large cohort of Belgian systemic sclerosis patients. Clinical Chemistry and Laboratory Medicine, 2020, 58, 416-423.	1.4	8
17	Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study. Seminars in Arthritis and Rheumatism, 2021, 51, 969-976.	1.6	8
18	Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application. Journal of Translational Autoimmunity, 2022, 5, 100141.	2.0	8

#	Article	IF	Citations
19	Specific Antinuclear Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis Are Associated with Improvement of Skin Thickening. Journal of Rheumatology, 2016, 43, 247-249.	1.0	7
20	Impact of the routine implementation of automated indirect immunofluorescence antinuclear antibody analysis: 1 year of experience. Clinical Chemistry and Laboratory Medicine, 2016, 54, e183-6.	1.4	6
21	IgA rheumatoid factor in rheumatoid arthritis. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1617-1626.	1.4	6
22	Relevance of Different Results of Different Antiâ€“Doubleâ€Stranded DNA Assays in Reporting Clinical Studies: Comment on the Article by Petri et al. Arthritis and Rheumatology, 2014, 66, 479-480.	2.9	5
23	Positioning of myositis-specific and associated autoantibody (MSA/MAA) testing in disease criteria and routine diagnostic work-up. Journal of Translational Autoimmunity, 2022, 5, 100148.	2.0	4
24	Fluoroenzymeimmunoassay to detect systemic sclerosis-associated antibodies: diagnostic performance and correlation with conventional techniques. Clinical and Experimental Rheumatology, 2012, 30, 748-55.	0.4	4
25	Pitfalls in the detection of myositis specific antibodies by lineblot in clinically suspected idiopathic inflammatory myopathy. Clinical and Experimental Rheumatology, 2020, 38, 212-219.	0.4	4
26	Autoantibodies and Donor-specific Antibodies are Associated With Graft Dysfunction in Pediatric Liver Transplantation. Journal of Pediatric Gastroenterology and Nutrition, 2021, 72, 661-666.	0.9	3
27	Authorsâ€™ reply to the Letter by Infantino et al. commenting on Bonroy et al.: Anti-DFS70 in different settings, CCLM 2018;56:1090â€“9. Clinical Chemistry and Laboratory Medicine, 2019, 57, e47-e48.	1.4	1
28	Repository of intra- and inter-run variations of quantitative autoantibody assays: a European multicenter study. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1373-1383.	1.4	1
29	Automated indirect immunofluorescence antinuclear antibody analysis is a standardized alternative for visual microscope interpretation. Clinical Chemistry and Laboratory Medicine, 2014, 52, .	1.4	0